Gene:
ADRB2
adrenergic, beta-2-, receptor, surface

PharmGKB contains no dosing guidelines for this gene. To report known dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this gene. To report a drug label with PGx, click here.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Position ? Drug ? Relevance ? Strength of
Evidence ?
rs1042713

To see relevance please register or sign in.

3
rs1042713

To see relevance please register or sign in.

3
rs1042714

To see relevance please register or sign in.

3

Download a summary of all Clinical Annotations available.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

PharmGKB contains no genetic tests for this gene. To report genetic tests, click here.

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(build 132) 		Alternate Names ? Drugs ? Alleles ?
(+ chr strand) 		Function ? Amino Acid?
Translation
rs1042713 46G>A, ADRB2:16Arg>Gly, ADRB2:Arg16Gly, ADRB2:Gly16Arg, Arg16, c.46A>G, g.5285A>G, g.9369367G>A, p.Arg16Gly
G > A
 Missense
Arg16Gly
rs1042714 318C>G, ADRB2:27Glu>Gln, ADRB2:79C>G, ADRB2:Gln27Glu, Gln27, c.79C>G, g.5318C>G, g.9369400G>C, p.Gln27Glu
G > C
 Missense
Gln27Glu
rs1800888 491T>C, ADRB2: 164Thr>Ile, Ile164, Thr164Ile, c.491C>T, g.148187078C>T, g.5730C>T, g.9369812C>T, p.Thr164Ile
C > T
 Missense
Thr164Ile
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP build 132

Overview

Alternate Names:  beta-2 adrenergic receptor; beta-2 adrenoceptor; beta-2 adrenoreceptor; catecholamine receptor
Alternate Symbols:  ADRB2R; ADRBR; B2AR; BAR; BETA2AR
PharmGKB Accession Id: PA39

Details

Cytogenetic Location: chr5 : q32 - q32
GP mRNA Boundary†: chr5 : 148206156 - 148208188
GP Gene Boundary†: chr5 : 148196156 - 148211188
Strand: plus
Product Name: No data available
† The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Antiarrhythmic Pathway, Pharmacodynamics
    Pharmacodynamic pathway of antiarrhythmic drugs in a stylized cardiac myocyte.
  1. Beta-agonist/Beta-blocker Pathway, Pharmacodynamics
    Simplified pharmacodynamic pathway of drug action on beta 2 adrenergic receptor in a stylized airway cell.
  1. Sympathetic Nerve Pathway (Neuroeffector Junction)
    Simplified diagram of a sympathetic neuroeffector junction displaying genes which may be involved.

External Pathways

Links to non-PharmGKB pathways.

  1. Arf6 signaling events - (Pathway Interaction Database NCI-Nature Curated)
  2. Arf6 trafficking events - (Pathway Interaction Database NCI-Nature Curated)
  3. corticosteroids and cardioprotection - (BioCarta via Pathway Interaction Database)
  4. cystic fibrosis transmembrane conductance regulator (cftr) and beta 2 adrenergic receptor (b2ar) pathway - (BioCarta via Pathway Interaction Database)
  5. phospholipase c-epsilon pathway - (BioCarta via Pathway Interaction Database)

Curated Information ?

Evidence Gene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
ADRBK1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
ADRBK2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
ARRB1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
ARRB2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
ELF2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
GNAI1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
GNAI2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
GNAI3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
GNAS
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
PLCB1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
PLCB2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
PLCB3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
PLCB4
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
PRKCA
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
PRKCB1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
PRKCD
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
PRKCDBP
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
PRKCE
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
PRKCG
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
PRKCH
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
PRKCQ
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
PRKCZ

Curated Information ?

Evidence Drug
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available PW
atenolol
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
budesonide
No Dosing Guideline available No Drug Label available CA VA No VIP available PW
carvedilol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
epinephrine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
fenoterol
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available PW
formoterol
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
indacaterol
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
isoproterenol
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
losartan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
metoprolol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
orciprenaline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
pindolol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
propranolol
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
risperidone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
ritodrine
No Dosing Guideline available No Drug Label available CA VA VIP PW
salbutamol
No Dosing Guideline available No Drug Label available CA VA No VIP available PW
salmeterol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
terbutaline
Evidence Drug Class
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA VIP No VIP available
Beta Blocking Agents
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
Beta blocking agents, non-selective
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
corticosteroids

Curated Information ?

Evidence Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Acute coronary syndrome
No Dosing Guideline available No Drug Label available CA VA VIP No VIP available
Asthma
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Coronary Artery Disease
No Dosing Guideline available No Drug Label available CA VA VIP No VIP available
Heart Failure
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Hypertension
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pulmonary Disease, Chronic Obstructive
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Schizophrenia

Publications related to ADRB2: 105

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of the heptahelical receptor regulators G-protein-coupled receptor kinases and arrestins: the known and the unknown. Pharmacogenomics. 2012. Lymperopoulos Anastasios, et al. [Article:22304582@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population. The pharmacogenomics journal. 2012. Almoguera B, et al. [Article:22212732@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics: the genetics of variable drug responses. Circulation. 2011. Roden Dan M, et al. [Article:21502584@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cardiovascular Pharmacogenomics of Adrenergic Receptor Signaling: Clinical Implications and Future Directions. Clinical pharmacology and therapeutics. 2011. Johnson J A, et al. [Article:21289619@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives. European journal of clinical pharmacology. 2011. Russo Roberta, et al. [Article:21069522@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of Hypertension Drug Target Genes With Blood Pressure and Hypertension in 86 588 Individuals. Hypertension. 2011. Johnson Andrew D, et al. [Article:21444836@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics. Pharmacogenomics. 2011. Sehrt Daniel, et al. [Article:21599570@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Influence of gene-gene interactions on response to albuterol therapy. Pharmacogenomics. 2011. Moore Paul E. [Article:21174616@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms, hypertension and thiazide diuretics. Pharmacogenomics. 2011. Citterio Lorena, et al. [Article:22044415@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A pharmacogenetic study of ADRB2 polymorphisms and indacaterol response in COPD patients. The pharmacogenomics journal. 2011. Yelensky R, et al. [Article:22158330@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The pharmacogenetics and pharmacogenomics of asthma therapy. The pharmacogenomics journal. 2011. Tse S M, et al. [Article:21987090@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. American journal of respiratory and critical care medicine. 2010. Bleecker Eugene R, et al. [Article:19910613@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Promoter Polymorphisms in the beta-2 Adrenergic Receptor Are Associated With Drug-Induced Gene Expression Changes and Response in Acute Lymphoblastic Leukemia. Clinical pharmacology and therapeutics. 2010. Pottier N, et al. [Article:20981007@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study. Pharmacogenetics and genomics. 2010. Nordestgaard Børge G, et al. [Article:20065889@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GSNO reductase and beta2-adrenergic receptor gene-gene interaction: bronchodilator responsiveness to albuterol. Pharmacogenetics and genomics. 2010. Choudhry Shweta, et al. [Article:20335826@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Very important pharmacogene summary ADRB2. Pharmacogenetics and genomics. 2010. Litonjua Augusto A, et al. [Article:19927042@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics in reproductive and perinatal medicine. Pharmacogenomics. 2010. Alfirevic Ana, et al. [Article:20017673@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities. Pharmacogenomics. 2010. Hersh Craig P. [Article:20136362@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common ADRB2 haplotypes derived from 26 polymorphic sites direct beta2-adrenergic receptor expression and regulation phenotypes. PloS one. 2010. Panebra Alfredo, et al. [Article:20686604@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Annals of neurology. 2009. Yalcin Ipek, et al. [Article:19259968@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Acute and chronic lung function responses to salmeterol and salmeterol plus fluticasone propionate in relation to Arg16Gly beta(2)-adrenergic polymorphisms. Current medical research and opinion. 2009. Yancey Steven W, et al. [Article:19275519@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arrhythmia pharmacogenomics: methodological considerations. Current pharmaceutical design. 2009. Roden Dan M, et al. [Article:19925424@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet. 2009. Wechsler Michael E, et al. [Article:19932356@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Beta2-adrenoceptors are essential for desipramine, venlafaxine or reboxetine action in neuropathic pain. Neurobiology of disease. 2009. Yalcin Ipek, et al. [Article:19084064@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Predicting response to short-acting bronchodilator medication using Bayesian networks. Pharmacogenomics. 2009. Himes Blanca E, et al. [Article:19761364@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
beta1- and beta2-adrenergic receptor gene variation, beta-blocker use and risk of myocardial infarction and stroke. American journal of hypertension. 2008. Lemaitre Rozenn N, et al. [Article:18219297@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clinical pharmacology and therapeutics. 2008. Pacanowski M A, et al. [Article:18615004@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Ile164 variant of beta2-adrenoceptor does not influence outcome in heart failure but may interact with beta blocker treatment. European journal of heart failure. 2008. Littlejohn Mathew D, et al. [Article:18068431@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Common beta-adrenergic receptor polymorphisms are not associated with risk of sudden cardiac death in patients with coronary artery disease. Heart rhythm : the official journal of the Heart Rhythm Society. 2008. Tseng Zian H, et al. [Article:18534365@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Effects of Ile164 polymorphism of beta2-adrenergic receptor gene on coronary artery disease. Journal of the American College of Cardiology. 2008. Piscione Federico, et al. [Article:18940527@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. Journal of the American College of Cardiology. 2008. Sehnert Amy J, et al. [Article:18702968@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Estimating coverage and power for genetic association studies using near-complete variation data. Nature genetics. 2008. Bhangale Tushar R, et al. [Article:18568023@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Influence of beta2-adrenoceptor polymorphisms on the response to chronic use of albuterol in asthmatic children. Pediatric pulmonology. 2008. Giubergia Verónica, et al. [Article:18383333@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The Arg16Gly variant of the beta2-adrenergic receptor predisposes to hypoglycemia unawareness in type 1 diabetes mellitus. Pharmacogenetics and genomics. 2008. Schouwenberg Bas J, et al. [Article:18334922@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical consequences of ADRbeta2 polymorphisms. Pharmacogenomics. 2008. Hawkins Gregory A, et al. [Article:18303970@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic response to albuterol among asthmatics. Pharmacogenomics. 2008. Corvol Harriet, et al. [Article:18466098@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Beta-adrenergic receptor gene polymorphisms and hemodynamic response to dobutamine during dobutamine stress echocardiography. The pharmacogenomics journal. 2008. Aquilante C L, et al. [Article:18253135@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Evidence for coexistence of three beta-adrenoceptor subtypes in human peripheral lymphocytes. Clinical pharmacology and therapeutics. 2007. Yu Xi-Yong, et al. [Article:17361123@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet. 2007. Bleecker Eugene R, et al. [Article:18156033@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association analyses of adrenergic receptor polymorphisms with obesity and metabolic alterations. Metabolism: clinical and experimental. 2007. Lima John J, et al. [Article:17512307@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenetics and genomics. 2007. Chen Lu, et al. [Article:18075464@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interaction between beta2 adrenergic receptor polymorphisms determines the extent of isoproterenol-induced vasodilatation ex vivo. Pharmacogenetics and genomics. 2007. Khalaila Jawad M, et al. [Article:17885618@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science (New York, N.Y.). 2007. Cherezov Vadim, et al. [Article:17962520@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. The American journal of cardiology. 2007. Shin Jaekyu, et al. [Article:17223428@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of beta2-adrenoreceptor gene variants on cardiac cavity size and systolic function in idiopathic dilated cardiomyopathy. The pharmacogenomics journal. 2007. Badenhorst D, et al. [Article:17117186@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of the human beta-adrenergic receptors. The pharmacogenomics journal. 2007. Taylor M R G. [Article:16636683@PubMed]
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
beta-Adrenergic receptor polymorphisms and response to salmeterol. American journal of respiratory and critical care medicine. 2006. Wechsler Michael E, et al. [Article:16322642@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A genetic analysis of opioid-induced hyperalgesia in mice. Anesthesiology. 2006. Liang De-Yong, et al. [Article:16645459@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Beta-2 adrenergic receptor gene (ADRB2) polymorphism and risk for lung adenocarcinoma: a case-control study in a Chinese population. Cancer letters. 2006. Wang Haijian, et al. [Article:16289313@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Beta2-adrenergic receptor genetic variants and risk of sudden cardiac death. Circulation. 2006. Sotoodehnia Nona, et al. [Article:16618831@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Beta2-adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension. Clinical pharmacology and therapeutics. 2006. Iaccarino Guido, et al. [Article:17178264@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. The Journal of allergy and clinical immunology. 2006. Johnson Malcolm. [Article:16387578@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. The Journal of allergy and clinical immunology. 2006. Bleecker Eugene R, et al. [Article:17030231@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Overview of the pharmacogenetics of asthma treatment. The pharmacogenomics journal. 2006. Weiss S T, et al. [Article:16568148@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Systematic review and meta-analysis of the association between {beta}2-adrenoceptor polymorphisms and asthma: a HuGE review. American journal of epidemiology. 2005. Thakkinstian Ammarin, et al. [Article:15987731@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arg16 homozygosity of the beta2-adrenergic receptor improves the outcome after beta2-agonist tocolysis for preterm labor. Clinical pharmacology and therapeutics. 2005. Landau Ruth, et al. [Article:16338281@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA : the journal of the American Medical Association. 2005. Lanfear David E, et al. [Article:16189366@PubMed]
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenetics and genomics. 2005. de Groote Pascal, et al. [Article:15861037@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Meta-analysis of the association of beta2-adrenergic receptor polymorphisms with asthma phenotypes. The Journal of allergy and clinical immunology. 2005. Contopoulos-Ioannidis Despina G, et al. [Article:15867853@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
ADRB2 polymorphisms and asthma susceptibility: transmission disequilibrium test and meta-analysis. International archives of allergy and immunology. 2004. Migita Ohsuke, et al. [Article:15153795@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet. 2004. Israel Elliot, et al. [Article:15500895@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Beta2-adrenoceptor Thr164Ile polymorphism is associated with markedly decreased vasodilator and increased vasoconstrictor sensitivity in vivo. Pharmacogenetics. 2004. Dishy Victor, et al. [Article:15284533@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Distinct roles for Src tyrosine kinase in beta2-adrenergic receptor signaling to MAPK and in receptor internalization. The Journal of biological chemistry. 2004. Huang Jianyun, et al. [Article:14990578@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacology and physiology of human adrenergic receptor polymorphisms. Annual review of pharmacology and toxicology. 2003. Small Kersten M, et al. [Article:12540746@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Salmeterol (Serevent) asthma trial halted early. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2003. Wooltorton Eric. [Article:12642431@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mechanisms of regulation of the expression and function of G protein-coupled receptor kinases. Cellular signalling. 2003. Penela Petronila, et al. [Article:14499340@PubMed]
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics. 2003. Kaye David M, et al. [Article:12835612@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Family-based association analysis of beta2-adrenergic receptor polymorphisms in the childhood asthma management program. The Journal of allergy and clinical immunology. 2003. Silverman Edwin K, et al. [Article:14610472@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Trafficking patterns of beta-arrestin and G protein-coupled receptors determined by the kinetics of beta-arrestin deubiquitination. The Journal of biological chemistry. 2003. Shenoy Sudha K, et al. [Article:12574160@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Antithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradox. The Journal of clinical investigation. 2003. McGraw Dennis W, et al. [Article:12925702@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Obesity risk is associated with carbohydrate intake in women carrying the Gln27Glu beta2-adrenoceptor polymorphism. The Journal of nutrition. 2003. Martínez J Alfredo, et al. [Article:12888635@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Beta(2)-adrenergic receptor polymorphism and nitric oxide-dependent forearm blood flow responses to isoproterenol in humans. The Journal of physiology. 2003. Garovic Vesna D, et al. [Article:12527744@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of asthma. American journal of respiratory and critical care medicine. 2002. Palmer Lyle J, et al. [Article:11934710@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annual review of pharmacology and toxicology. 2002. Angers Stephane, et al. [Article:11807178@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms in beta-adrenergic receptor genes in the acquired long QT syndrome. Journal of cardiovascular electrophysiology. 2002. Kanki Hideaki, et al. [Article:11942593@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Beta-adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogenetics. Pharmaceutical research. 2002. Johnson Julie A, et al. [Article:12523655@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
beta2 adrenoceptor gene polymorphisms in cystic fibrosis lung disease. Pharmacogenetics. 2002. Büscher Rainer, et al. [Article:12142724@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Progress in neurobiology. 2002. Claing Audrey, et al. [Article:11900882@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science (New York, N.Y.). 2002. Perry Stephen J, et al. [Article:12399592@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Update on current concepts of the molecular basis of beta2-adrenergic receptor signaling. The Journal of allergy and clinical immunology. 2002. Liggett Stephen B. [Article:12464928@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Beta-blockade in heart failure: selective versus nonselective agents. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2001. Metra M, et al. [Article:14728047@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of asthma with beta(2)-adrenergic receptor gene polymorphism and cigarette smoking. American journal of respiratory and critical care medicine. 2001. Wang Z, et al. [Article:11371409@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s). European journal of pharmacology. 2001. Green S A, et al. [Article:11516429@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma. International archives of allergy and immunology. 2001. Israel E, et al. [Article:11306963@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. The New England journal of medicine. 2001. Dishy V, et al. [Article:11586955@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
beta2-adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals. American heart journal. 2000. Hoit B D, et al. [Article:10689270@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. American journal of respiratory and critical care medicine. 2000. Israel E, et al. [Article:10903223@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Beta(2)-adrenoceptor polymorphism determines vascular reactivity in humans. Hypertension. 2000. Cockcroft J R, et al. [Article:10988267@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional receptor coupling to Gi is a mechanism of agonist-promoted desensitization of the beta2-adrenergic receptor. Journal of receptor and signal transduction research. 2000. Tepe N M, et al. [Article:10711498@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proceedings of the National Academy of Sciences of the United States of America. 2000. Drysdale C M, et al. [Article:10984540@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax. 2000. Taylor D R, et al. [Article:10950895@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clinical pharmacology and therapeutics. 1999. Lima J J, et al. [Article:10340917@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
beta-2 Adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians. Hypertension. 1999. Gratze G, et al. [Article:10373227@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tolerance to beta-agonists during acute bronchoconstriction. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 1999. Hancox R J, et al. [Article:10515402@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
beta2-Adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma. American journal of respiratory and critical care medicine. 1998. Weir T D, et al. [Article:9731005@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The beta2-adrenergic receptor interacts with the Na+/H+-exchanger regulatory factor to control Na+/H+ exchange. Nature. 1998. Hall R A, et al. [Article:9560162@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. The Journal of clinical investigation. 1998. Liggett S B, et al. [Article:9788966@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Alpha 2A-adrenergic receptor stimulated calcium release is transduced by Gi-associated G(beta gamma)-mediated activation of phospholipase C. Biochemistry. 1997. Dorn G W, et al. [Article:9174358@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature. 1997. Daaka Y, et al. [Article:9363896@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. The Journal of clinical investigation. 1997. Martinez F D, et al. [Article:9399966@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 1994. Green S A, et al. [Article:7915137@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacology and molecular biology of adrenergic receptors. Baillière's clinical endocrinology and metabolism. 1993. Liggett S B, et al. [Article:8489482@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. The Journal of biological chemistry. 1993. Green S A, et al. [Article:7901205@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Phosphorylation sites on two domains of the beta 2-adrenergic receptor are involved in distinct pathways of receptor desensitization. The Journal of biological chemistry. 1989. Hausdorff W P, et al. [Article:2545714@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proceedings of the National Academy of Sciences of the United States of America. 1987. Kobilka B K, et al. [Article:3025863@PubMed]
PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (R24 GM61374).
©2001-2012 PharmGKB.